SCHEMBL14935706

SCHEMBL14935706

CC(=O)CCCCc1ccccc1O

nearest known ligand 0.56

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
IAPP P10997 2/20 0.56
MGLL Q99685 1/20 0.51
CYP4F2 P78329 1/20 0.47
CYP4A11 Q02928 1/20 0.47
MPO P05164 2/20 0.47
SLC6A4 P31645 1/20 0.47
TAAR1 Q96RJ0 1/20 0.47
AKR1B1 P15121 1/20 0.47
ALDH1A1 P00352 1/20 0.46
BID P55957 4/20 0.45
MCL1 Q07820 4/20 0.45
BCL2L1 Q07817 3/20 0.45
BAK1 Q16611 3/20 0.45
KAT8 Q9H7Z6 2/20 0.45
PPARG P37231 1/20 0.45
PPARA Q07869 1/20 0.45
EP300 Q09472 1/20 0.45
KAT2A Q92830 1/20 0.45
KAT2B Q92831 1/20 0.45
KAT5 Q92993 1/20 0.45

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9343713 0.98 IAPP (0.54) IAPPMGLLCYP4F2CYP4A11MPO
SCHEMBL29191321 0.94 IAPP (0.58) IAPPMGLLMPOSLC6A4TAAR1
SCHEMBL9394677 0.86 CYP4F2 (0.51) IAPPCYP4F2CYP4A11ALDH1A1
SCHEMBL29934495 0.86 IAPP (0.72) IAPPMGLLCYP4F2CYP4A11MPO
SCHEMBL269353 0.86 IAPP (0.72) IAPPMGLLCYP4F2CYP4A11MPO
SCHEMBL29086130 0.84 IAPP (0.75) IAPPBIDMCL1BCL2L1BAK1
SCHEMBL29086100 0.84 IAPP (0.75) IAPPBIDMCL1BCL2L1BAK1
SCHEMBL3623274 0.83 AKR1B1 (0.59) IAPPMGLLMPOSLC6A4TAAR1
SCHEMBL28486763 0.83 MGLL (0.57) IAPPMGLLCYP4F2CYP4A11MPO
SCHEMBL3800530 0.82 TAAR1 (0.65) MGLLMPOSLC6A4TAAR1AKR1B1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-3103797-B1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN INC (US) 2019-04-10 EP disclosed
EP-3103797-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2016-12-14 EP disclosed
EP-2776403-B1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN INC (US) 2016-09-14 EP disclosed
US-20130123215-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS ALLERGAN, INC. (US) 2013-05-16 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20130123215-A1 2,5-DIOXOIMIDAZOLIDIN-1-YL-3-PHENYLUREA DERIVATIVES AS FORMYL PEPTIDE RECEPTOR LIKE-1 (FPRL-1) RECEPTOR MODULATORS FPR1, FPR2, FPR3 IAPP 913/4885MGLL 609/4885CYP4F2 2424/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.